4.6 Review

Epi-drugs to fight cancer: From chemistry to cancer treatment, the road ahead

Journal

Publisher

PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.biocel.2008.08.020

Keywords

Epigenetics; Chromatin remodelling; DNA methyltransferase; Histone deacetylase; Histone acetyltransferase; Histone methyltransferase; Histone demethylase

Funding

  1. EU
  2. APO-SYS [200767]
  3. PRIN 2006
  4. La Regione Campania L5 annualita 2005
  5. FIRB [RBIP067F9E]
  6. RETI FIRB [RBPR05NWWC_006]
  7. Associazione Italiana per la Ricerca sul Cancro Funding Source: Custom

Ask authors/readers for more resources

In addition to genetic events, a variety of epigenetic events have been widely reported to contribute to file Onset of many diseases including cancer. DNA methylation and historic modifications (such as acetylation, methylation, sumoylation, and phosphorylation) involving chromatin remodelling are among the most studied epigenetic mechanisms for regulation of gene expression leading, when altered, to some diseases. Epigenetic therapy tries to reverse the aberrations followed to the disruption of the balance of the epigenetic signalling ways through the use of both natural compounds and synthetic molecules, active on Specific epi-targets. Such epi-drugs are, for example, inhibitors of DNA methyltransferases, histone deacetylases, histone acetyltransferases, histone methyltransferases, and histone demethylases. In this review we will focus Oil the chemical aspects Of such molecules joined to their effective (or potential) application in cancer therapy. (C) 2008 Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available